✦ LIBER ✦

W1242 Patient Preferences for Subcutaneous Versus Intravenous Formulations of Anti-TNF Agents for Treatment of Inflammatory Bowel Disease

✍ Scribed by Pitchumoni, Suresh; Scherl, Ellen J.; Bosworth, Brian P.; Lee, Thomas C.; Poles, Michael A.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mo1199 Characteristics and Outcome of Ps

✍ Gadani, Akash; George, Lauren; Jambaulikar, Guruprasad D.; Cross, Raymond; Ghazi 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 416 KB

Safety of Immunomodulators and Anti-TNF

✍ Casanova, María José ;Chaparro, Maria ;Iglesias Flores, Eva ;Rodrigo, Luis ;Domè 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 124 KB

P408 Safety of immunomodulators and anti

✍ M.J. Casanova; M. Chaparro; E. Doménech; M. Barreiro-de Acosta; F. Bermejo; E. I 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 52 KB

Sa1933 Safety of Immunomodulators and An

✍ Casanova, Maria José; Chaparro, Maria; Domenech, Eugeni; Acosta, Manuel Barreiro 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 77 KB

Assessing Patient Preferences for Treatm

✍ Bewtra, Meenakshi; Johnson, F. Reed 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 333 KB

T1272 Screening Patients Initiating Anti

✍ Greveson, Kay; Murray, Charles; Toumpanakis, Christos; Epstein, Owen; Baptista, 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 98 KB